Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Gnanasakthy

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2013
Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010)Carla DeMuro, Marci Clark, Lynda Doward, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 8, 2024
Critical Comments by Food and Drug Administration Reviewers on Patient-Reported Outcomes in Food and Drug Administration Regulatory Submissions (2018-2021)Christina Slota, Lindsey Norcross, Erin Comerford, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2012
A review of patient-reported outcome labels in the United States: 2006 to 2010Ari Gnanasakthy, Margaret Mordin, Marci Clark, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2012
Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010Carla DeMuro, Marci Clark, Margaret Mordin, et al.
Gastroenterology Research|December 14, 2016
Urgency as an Endpoint in Irritable Bowel SyndromeAllen W Mangel, Jianmin Wang, Beth Sherrill, et al.
Advances in Therapy|February 3, 2016
Assessing Changes in Chronic Spontaneous/Idiopathic Urticaria: Comparisons of Patient-Reported Outcomes Using Latent Growth ModelingDonald E Stull, Doreen McBride, Katherine Houghton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 24, 2026
Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023)Courtney Levy, Sarah Sauchelli, Jessica L Abel, et al.
Frontiers in Pharmacology|April 28, 2025
From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018-2022)Sarah Sauchelli, Courtney Levy, Ari Gnanasakthy, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 5, 2005
Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrumentKathleen J Yost, Mark V Sorensen, Elizabeth A Hahn, et al.
American Heart Journal|June 25, 2004
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Shelby D Reed, Joëlle Y Friedman, Eric J Velazquez, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2013
Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010)Carla DeMuro, Marci Clark, Lynda Doward, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 8, 2024
Critical Comments by Food and Drug Administration Reviewers on Patient-Reported Outcomes in Food and Drug Administration Regulatory Submissions (2018-2021)Christina Slota, Lindsey Norcross, Erin Comerford, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2012
A review of patient-reported outcome labels in the United States: 2006 to 2010Ari Gnanasakthy, Margaret Mordin, Marci Clark, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2012
Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010Carla DeMuro, Marci Clark, Margaret Mordin, et al.
Gastroenterology Research|December 14, 2016
Urgency as an Endpoint in Irritable Bowel SyndromeAllen W Mangel, Jianmin Wang, Beth Sherrill, et al.
Advances in Therapy|February 3, 2016
Assessing Changes in Chronic Spontaneous/Idiopathic Urticaria: Comparisons of Patient-Reported Outcomes Using Latent Growth ModelingDonald E Stull, Doreen McBride, Katherine Houghton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 24, 2026
Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023)Courtney Levy, Sarah Sauchelli, Jessica L Abel, et al.
Frontiers in Pharmacology|April 28, 2025
From clinical trials to informing clinical decision-making: a review of patient-reported outcomes in nononcology medicines approved by the European Medicines Agency (2018-2022)Sarah Sauchelli, Courtney Levy, Ari Gnanasakthy, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 5, 2005
Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrumentKathleen J Yost, Mark V Sorensen, Elizabeth A Hahn, et al.
American Heart Journal|June 25, 2004
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Shelby D Reed, Joëlle Y Friedman, Eric J Velazquez, et al.
Pageof 6